[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509757":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":54,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Iowa","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"metformin","ACTIVE_COMPARATOR",null,[13],"Drug: Metformin Hydrochloride",{"label":15,"type":16,"description":11,"interventionNames":17},"placebo","PLACEBO_COMPARATOR",[18],"Other: placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Metformin Hydrochloride","12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.",[9],{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.",[15],[29],{"name":30,"affiliation":5,"role":31},"Anna Stanhewicz, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":11,"email":36},"CONTACT","3194671732","anna-stanhewicz@uiowa.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-91.53017,41.66113,{"lat":49,"lon":48},[52],{"name":30,"role":34,"phone":53,"phoneExt":11,"email":36},"319-467-1732",{"type":55,"investigatorFullName":30,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Assistant Professor","100509757","early-phase-1-metformin-for-the-treatment-of-microvascular-dysfunction-after-gestational-diabetes-100509757",false,"NCT05917587","Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes","Inclusion Criteria:\n\n* ≥12 weeks and ≤5 years postpartum\n* history of GDM or healthy pregnancy\n\nExclusion Criteria:\n\n* prediabetes or diabetes (HbA1c ≥5.7%)\n* current tobacco use\n* cardiovascular or metabolic disease\n* cardiovascular or metabolic medication\n* history of hypertension during pregnancy\n* current pregnancy",true,"FEMALE","18 Years","45 Years",{"count":68,"type":69},30,"ESTIMATED","INTERVENTIONAL",[72],"EARLY_PHASE1","The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.",[75],"Gestational Diabetes",[77,78,79],"gestational diabetes","postpartum","vascular","2025-05-07",{"date":82,"type":83},"2025-05-13","ACTUAL",{"date":85,"type":83},"2024-09-11",{"date":87,"type":69},"2028-06-30",{"name":30,"class":6},1]